Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 23 studies | 33% ± 14% | |
| astrocyte | 14 studies | 37% ± 18% | |
| pericyte | 11 studies | 28% ± 12% | |
| oligodendrocyte precursor cell | 11 studies | 38% ± 19% | |
| microglial cell | 11 studies | 33% ± 13% | |
| fibroblast | 11 studies | 29% ± 13% | |
| oligodendrocyte | 11 studies | 38% ± 14% | |
| smooth muscle cell | 10 studies | 26% ± 8% | |
| GABAergic neuron | 9 studies | 46% ± 24% | |
| glutamatergic neuron | 9 studies | 50% ± 25% | |
| adipocyte | 9 studies | 31% ± 9% | |
| mast cell | 9 studies | 24% ± 8% | |
| macrophage | 8 studies | 32% ± 13% | |
| natural killer cell | 6 studies | 21% ± 6% | |
| neuron | 6 studies | 39% ± 18% | |
| epithelial cell | 6 studies | 30% ± 14% | |
| endothelial cell of lymphatic vessel | 6 studies | 31% ± 11% | |
| interneuron | 5 studies | 56% ± 23% | |
| dendritic cell | 5 studies | 19% ± 2% | |
| ciliated cell | 5 studies | 24% ± 7% | |
| T cell | 5 studies | 23% ± 5% | |
| monocyte | 5 studies | 25% ± 5% | |
| type I pneumocyte | 5 studies | 23% ± 8% | |
| type II pneumocyte | 5 studies | 33% ± 8% | |
| granule cell | 4 studies | 30% ± 6% | |
| B cell | 4 studies | 23% ± 7% | |
| CD8-positive, alpha-beta T cell | 4 studies | 19% ± 4% | |
| cardiac muscle cell | 4 studies | 31% ± 2% | |
| lymphocyte | 4 studies | 32% ± 13% | |
| Mueller cell | 4 studies | 25% ± 6% | |
| amacrine cell | 4 studies | 23% ± 5% | |
| retina horizontal cell | 4 studies | 26% ± 7% | |
| retinal rod cell | 4 studies | 26% ± 7% | |
| endothelial cell of vascular tree | 4 studies | 31% ± 18% | |
| club cell | 4 studies | 26% ± 7% | |
| CD16-positive, CD56-dim natural killer cell, human | 3 studies | 21% ± 6% | |
| plasma cell | 3 studies | 25% ± 5% | |
| CD16-negative, CD56-bright natural killer cell, human | 3 studies | 20% ± 3% | |
| CD4-positive, alpha-beta T cell | 3 studies | 20% ± 2% | |
| mesothelial cell | 3 studies | 25% ± 9% | |
| vein endothelial cell | 3 studies | 35% ± 18% | |
| GABAergic amacrine cell | 3 studies | 25% ± 7% | |
| glycinergic amacrine cell | 3 studies | 24% ± 2% | |
| myeloid cell | 3 studies | 20% ± 3% | |
| abnormal cell | 3 studies | 25% ± 10% | |
| myofibroblast cell | 3 studies | 31% ± 9% | |
| alveolar macrophage | 3 studies | 30% ± 7% | |
| capillary endothelial cell | 3 studies | 23% ± 4% | |
| respiratory goblet cell | 3 studies | 31% ± 12% | |
| muscle cell | 3 studies | 36% ± 20% | |
| basal cell | 3 studies | 36% ± 17% | |
| goblet cell | 3 studies | 32% ± 19% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 2250.30 | 1445 / 1445 | 100% | 15.29 | 183 / 183 |
| lung | 100% | 2982.06 | 578 / 578 | 99% | 12.54 | 1147 / 1155 |
| brain | 99% | 1865.24 | 2616 / 2642 | 100% | 13.58 | 704 / 705 |
| pancreas | 100% | 1644.16 | 327 / 328 | 98% | 12.75 | 175 / 178 |
| prostate | 100% | 2627.93 | 245 / 245 | 98% | 13.61 | 492 / 502 |
| thymus | 100% | 2705.23 | 653 / 653 | 98% | 12.90 | 591 / 605 |
| breast | 100% | 2883.86 | 459 / 459 | 97% | 16.80 | 1089 / 1118 |
| stomach | 100% | 1968.15 | 359 / 359 | 97% | 11.79 | 276 / 286 |
| intestine | 100% | 2852.31 | 966 / 966 | 96% | 10.44 | 508 / 527 |
| kidney | 100% | 1583.43 | 89 / 89 | 94% | 11.03 | 848 / 901 |
| bladder | 100% | 3010.24 | 21 / 21 | 93% | 8.53 | 470 / 504 |
| skin | 100% | 2215.22 | 1809 / 1809 | 93% | 13.16 | 437 / 472 |
| uterus | 100% | 3444.45 | 170 / 170 | 92% | 8.54 | 421 / 459 |
| adrenal gland | 100% | 2210.42 | 258 / 258 | 90% | 11.14 | 208 / 230 |
| ovary | 100% | 2623.51 | 180 / 180 | 79% | 4.74 | 340 / 430 |
| liver | 99% | 933.15 | 224 / 226 | 67% | 4.30 | 274 / 406 |
| adipose | 100% | 3118.99 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 3118.35 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 100% | 2592.15 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 2360.24 | 241 / 241 | 0% | 0 | 0 / 0 |
| heart | 97% | 1843.48 | 837 / 861 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 93% | 6.97 | 42 / 45 |
| lymph node | 0% | 0 | 0 / 0 | 90% | 9.02 | 26 / 29 |
| peripheral blood | 75% | 1237.60 | 693 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 66% | 5.47 | 53 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0032007 | Biological process | negative regulation of TOR signaling |
| GO_0016567 | Biological process | protein ubiquitination |
| GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
| GO_0071596 | Biological process | ubiquitin-dependent protein catabolic process via the N-end rule pathway |
| GO_0071233 | Biological process | cellular response to L-leucine |
| GO_0000502 | Cellular component | proteasome complex |
| GO_0000151 | Cellular component | ubiquitin ligase complex |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0061630 | Molecular function | ubiquitin protein ligase activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0070728 | Molecular function | L-leucine binding |
| GO_0008270 | Molecular function | zinc ion binding |
| Gene name | UBR1 |
| Protein name | Alternative protein UBR1 E3 ubiquitin-protein ligase UBR1 (EC 2.3.2.27) (N-recognin-1) (RING-type E3 ubiquitin transferase UBR1) (Ubiquitin-protein ligase E3-alpha-1) (Ubiquitin-protein ligase E3-alpha-I) E3 ubiquitin-protein ligase (EC 2.3.2.27) Ubiquitin protein ligase E3 component n-recognin 1 |
| Synonyms | |
| Description | FUNCTION: E3 ubiquitin-protein ligase which is a component of the N-end rule pathway. Recognizes and binds to proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule, leading to their ubiquitination and subsequent degradation. May be involved in pancreatic homeostasis. Binds leucine and is a negative regulator of the leucine-mTOR signaling pathway, thereby controlling cell growth. . FUNCTION: Ubiquitin ligase protein which is a component of the N-end rule pathway. Recognizes and binds to proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule, leading to their ubiquitination and subsequent degradation. . FUNCTION: Ubiquitin ligase protein which is a component of the N-end rule pathway. Recognizes and binds to proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule, leading to their ubiquitination and subsequent degradation. . FUNCTION: Ubiquitin ligase protein which is a component of the N-end rule pathway. Recognizes and binds to proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule, leading to their ubiquitination and subsequent degradation. . FUNCTION: Ubiquitin ligase protein which is a component of the N-end rule pathway. Recognizes and binds to proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule, leading to their ubiquitination and subsequent degradation. . |
| Accessions | H3BUZ4 H3BQF8 ENST00000569971.5 ENST00000290650.9 [Q8IWV7-1] H3BS20 L8E998 ENST00000563239.1 H3BUC4 A0A0C4DGM0 Q8IWV7 ENST00000627960.1 ENST00000569066.2 A0A087WTJ9 ENST00000546274.6 ENST00000569243.5 ENST00000569337.1 H3BNQ6 ENST00000564540.5 |